Laying the Groundwork for a Biotech Rebound
Despite the spring’s bad headlines, this summer ended with a pile of venture capital deals and two more Bay State biotech IPOs. It’s time for Beacon Hill to do its part to keep that momentum going.
Despite the spring’s bad headlines, this summer ended with a pile of venture capital deals and two more Bay State biotech IPOs. It’s time for Beacon Hill to do its part to keep that momentum going.
We believe the projects most likely to succeed are those situated in dynamic ecosystems that already exist and can help foster innovation and collaboration.
The life sciences and lab market across the Boston metro area has been in a state of flux for some time, but a new factors have added extra pressure on landlords and owners.